Gary Middleton

Professor Gary Middleton serves as Professor of Medical Oncology, Immunology and Immunotherapy at the Birmingham Experimental Cancer Research Centre, University of Birmingham. He directs significant research initiatives in cancer therapeutics with particular expertise in lung cancer and immunotherapy approaches.

His research interests encompass multiple critical areas of oncology including:

• Medical Oncology with specialized focus on lung cancer treatment
• Immunology and immunotherapy mechanisms
• Colorectal cancer therapeutics
• Cancer clinical trial design and implementation
• Molecular biomarkers in cancer treatment response
• Novel combination therapies

Professor Middleton's recent publication activity demonstrates a strong emphasis on precision oncology approaches, particularly for non-small cell lung cancer. His work examines molecularly targeted therapies, immune checkpoint inhibitors, and novel combination strategies. The research reveals an increasing focus on biomarker-driven treatment selection and understanding mechanisms of therapeutic resistance across multiple cancer types.

He leads or contributes to multiple major research projects including:

• Thrombo-STOP: Apixaban thromboprophylaxis in ambulatory lung cancer patients
• CRC-STARS: Colorectal cancer stratification through adaptive responses
• CRUK CRCTU Core Funding for clinical trials
• Investigating Regulatory B cells in immune-related adverse events
• KETO-LUNG: Metabolic approach to lung cancer treatment

Professor Middleton has been instrumental in major clinical trials including the National Lung Matrix Trial, contributing innovative Bayesian adaptive phase II trial designs for testing multiple genetic-marker-directed drugs across multi-centre, multi-arm frameworks. His work has significantly impacted the field of precision oncology and cancer clinical trial methodology.